Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (221-230 of 387) with videos related to

Pageof 39
Sort By:
Cancer Cell|June 15, 2013
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomasLinfeng Chen, Stefano Monti, Przemyslaw Juszczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Blood|July 19, 2011
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemiaMatthew J Maurer, James R Cerhan, Jerry A Katzmann, et al.
International Journal of Molecular Epidemiology and Genetics|June 21, 2011
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphomaJames R Cerhan, Zachary S Fredericksen, Alice H Wang, et al.
Blood Advances|September 28, 2022
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosisSanjal H Desai, Raphael Mwangi, Wern Lynn Ng, et al.
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Haematologica|June 16, 2018
Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangementsEllen D McPhail, Matthew J Maurer, William R Macon, et al.
Blood Cancer Journal|July 18, 2021
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab eraArushi Khurana, Raphael Mwangi, Stephen M Ansell, et al.
Blood|March 19, 2011
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1Lucy S Hodge, Anne J Novak, Deanna M Grote, et al.
Pageof 39

Showing results (221-230 of 387) with videos related to

Sort By:
Pageof 39
Cancer Cell|June 15, 2013
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomasLinfeng Chen, Stefano Monti, Przemyslaw Juszczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Blood|July 19, 2011
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemiaMatthew J Maurer, James R Cerhan, Jerry A Katzmann, et al.
International Journal of Molecular Epidemiology and Genetics|June 21, 2011
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphomaJames R Cerhan, Zachary S Fredericksen, Alice H Wang, et al.
Blood Advances|September 28, 2022
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosisSanjal H Desai, Raphael Mwangi, Wern Lynn Ng, et al.
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Haematologica|June 16, 2018
Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangementsEllen D McPhail, Matthew J Maurer, William R Macon, et al.
Blood Cancer Journal|July 18, 2021
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab eraArushi Khurana, Raphael Mwangi, Stephen M Ansell, et al.
Blood|March 19, 2011
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1Lucy S Hodge, Anne J Novak, Deanna M Grote, et al.
Pageof 39